I-Mab Announces Closing of the Divestiture of Business Operations in China

ROCKVILLE, Md., April 2, 2024 /PRNewswire/ — I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks